Sudeep Pharma DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
	0.76×	0.76×
	1.07×	1.10×
	32.9%	32.2%
	0.55×	0.55×
	1.37×	1.31×
	20.0%	19.5%
	19.6%	19.6%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUDEEPPHRM₹1,130.10

Sudeep Pharma Ltd.

· Chemicals

₹ CrorePeersSUDARSCHEM STYRENIX SHARDACROP REFEX RCF RALLIS RAIN PRIVISCLMcap ₹12,764 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.76	0.76
Interest Burden (Pretax/EBIT) ×	1.10	1.07
EBIT Margin %	32.24	32.92
Asset Turnover ×	0.55	0.55
Financial Leverage (Assets/Equity) ×	1.31	1.37
ROE (5-step product, year-end total equity) %	19.52	19.97
ROE (owners' profit / average owners' equity) %	19.57	19.57

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.